The Peter Attia Drive

View the Show Notes Page for This Episode
Become a Member to Receive Exclusive Content
Sign Up to Receive Peter's Weekly Newsletter
In this episode, Peter takes a deep dive into prostate cancer screening, explaining why advanced and metastatic diagnoses continue to rise despite the availability of screening tools, and what can be done to reverse this trend. He breaks down what PSA actually measures and why it is far more informative when tracked over time rather than interpreted as a single value, and he explores how tools like MRI, PSA density, PSA velocity, and improved biopsy techniques can both reduce unnecessary procedures and improve the detection of aggressive cancers. Peter also discusses the role of active surveillance in avoiding overtreatment for low-risk cases, examines the flawed evidence that has historically been used to argue against PSA screening, and highlights how medications like finasteride can suppress PSA levels and potentially mask warning signs if not properly accounted for. Ultimately, he makes a compelling case for the importance of regular PSA testing as a key strategy in the effort to eliminate prostate cancer mortality.
We discuss:
The failure of current prostate cancer screening guidelines, and the rise in advanced disease despite available tools [2:30];
PSA screening fundamentals: benefits, harms, and the guideline shift driven by overdiagnosis concerns [5:30];
The impact of reduced PSA screening: rising rates of late-stage prostate cancer and worsening population-level outcomes [12:00];
How modern screening practices use PSA trends, MRI, and new imaging advances to improve accuracy and reduce unnecessary procedures [15:00];
Advances in prostate biopsy: transperineal approach improves safety and cancer detection [23:00];
Reducing overtreatment: Gleason scoring and active surveillance in modern prostate cancer care [25:30];
Reevaluating PSA screening guidelines: how flaws in the PLCO trial undermine the evidence used to argue against PSA screening [29:45];
Prostate cancer screening today: improved tools, flawed guidelines, and preventable mortality [33:45];
How finasteride and similar drugs suppress PSA levels and can lead to missed or delayed prostate cancer diagnoses if not properly accounted for [38:00];
The optimistic future of prostate cancer: modern screening advances and the potential to reduce mortality [43:15]; and
More.
Connect With Peter on Twitter, Instagram, Facebook and YouTube

View the Show Notes Page for This Episode
Become a Member to Receive Exclusive Content
Sign Up to Receive Peter's Weekly Newsletter
In this "Ask Me Anything" (AMA) episode, Peter explores the topic of gray-market peptides, one of the most requested and most confusing topics he's covered on The Drive. Peptides sit at the intersection of biological plausibility, clinical promise, and aggressive commercialization, and are often marketed as cutting-edge therapies for everything from muscle repair and longevity to cosmetic enhancement. Rather than promoting or dismissing peptides wholesale, Peter lays out a clear, repeatable framework for evaluating any peptide or drug—covering mechanism, intended effects, safety, dosing, and alternatives. He distinguishes FDA-approved peptide therapeutics from the loosely regulated "peptides" common in biohacking culture; examines the strengths and limitations of animal and human evidence; unpacks manufacturing, gray-market sales, "research use only" labeling, and third-party testing; addresses oral peptides and absorption challenges; and explains how patents and incentives shape which compounds advance through clinical pipelines. The discussion concludes with a sober look at what would need to change for peptides to become broadly usable therapies, where legitimate peptide therapeutics may expand next, and which areas of medicine stand to benefit most right now.
If you're not a subscriber and are listening on a podcast player, you'll only be able to hear a preview of the AMA. If you're a subscriber, you can now listen to this full episode on your private RSS feed or our website at the AMA #83 show notes page. If you are not a subscriber, you can learn more about the subscriber benefits here.
We discuss:
Setting the framework for evaluating peptides, and explaining the goal of this discussion [3:15];
What peptides are: basic definitions, biological roles, and therapeutic foundations [5:30];
A framework for evaluating peptides: mechanism, evidence, safety, and regulatory context [10:00];
Peptide case study—SS-31: mechanism of action, approved use in Barth syndrome, and other claimed effects [18:15];
Does the mechanistic rationale for SS-31 translate into measurable benefits? [22:15];
SS-31 continued: safety considerations, gray market risks, the balance of risk versus reward, and why it belongs in bucket #3 [26:00];
Peptide case study—melanotan-II: claimed effects, mechanism of action, safety, and side effects [30:45];
Melanotan-II continued: weighing the potential risks versus benefits and why it belongs in bucket #2 [36:30];
Peptide case study—CJC-1295: growth hormone–stimulating mechanism, claimed effects, and limited human data [40:15];
CJC-1295 continued: dosing uncertainty, risk-reward analysis, lack of long-term safety data, limited approved options, and why it belongs in bucket #2 [49:30];
Peptide case study—BPC 157: uncertain origins, broad claims, and weak mechanistic evidence [57:45];
BPC 157 continued: review of human evidence, lack of replication of animal data, safety considerations, risk-reward analysis, and why it belongs in bucket #1 [1:03:15];
Other popular "gray market" peptides and why they mostly fail when under scrutiny [1:11:15];
How the evidence on peptides compares to rapamycin, and why the lack of data is the biggest concern [1:20:00];
Understanding peptide regulation: FDA approval, supplement oversight, and the risks of gray-market compounds [1:23:00];
Inside the gray market: how peptides are sold, regulated, and why testing cannot guarantee safety [1:26:45];
Limitations of oral peptides, and examples of peptides in bucket #4 [1:31:45];
The future of peptides: real therapeutic potential versus hype in the wellness market [1:35:00]; and
More.
Connect With Peter on Twitter, Instagram, Facebook and YouTube

View the Show Notes Page for This Episode
Become a Member to Receive Exclusive Content
Sign Up to Receive Peter's Weekly Newsletter
In this episode, Peter takes a deep dive into the science and application of aging clocks, unpacking what they are, the differences between chronological age, biological age, and the pace of aging, and what epigenetic clocks may actually be measuring. He explores key research in the field, including a randomized controlled trial that tested simple lifestyle interventions against several commonly used aging clocks, as well as a study using brain MRI to assess the pace of aging and its relationship to dementia risk and mortality. Throughout the episode, Peter highlights the promises and pitfalls of these tools, ultimately focusing on the field's central question: whether improving an aging clock score truly translates into meaningful clinical outcomes.
We discuss:
Why aging clocks are being used as proxies for long-term health outcomes and the uncertainty surrounding their clinical value [2:00];
How aging clocks use DNA methylation to predict age and how they compare to traditional mortality prediction models [5:00];
The shift from aging clocks that predict chronological age to newer models that aim to measure biological age, lifespan differences, and the pace of aging [11:45];
The limitations of second-generation aging clocks: biological and measurement noise affecting reliability and interpretation [14:45];
Why aging clocks are exciting tools—compression, speed, and individual feedback [17:15];
The DO-HEALTH randomized trial: the study design and how different aging clocks were used to measure biological age and the pace of aging [22:00];
The DO-HEALTH study results: findings, takeaways, and open questions [27:45];
The DunedinPACNI study: how the model was developed and what it may add to the field [35:00];
The promise and limitations of aging clocks in measuring meaningful biological aging and predicting health outcomes [48:00];
Why aging clocks are not yet reliable as consumer tools and why traditional health metrics still matter most [52:00]; and
More.
Connect With Peter on Twitter, Instagram, Facebook and YouTube

View the Show Notes Page for This Episode
Become a Member to Receive Exclusive Content
Sign Up to Receive Peter's Weekly Newsletter
In this "Ask Me Anything" (AMA) episode, Peter answers listener questions across a wide range of topics, focusing on practical decision-making and real-world application. He explores how health priorities and strategies should evolve across different decades of life, which chronic diseases are most challenging to manage and how to think about risk hierarchies, and which emerging interventions—beyond exercise—show the most promise for dementia prevention. Peter also breaks down the utility of wearables and explains how to use and interpret DEXA scans effectively. He discusses the challenges of behavior change and how to make healthy habits stick, along with training strategies for balance, stability, and injury resilience, drawing lessons from his own setbacks. Additional topics include high-protein diets and mTOR, how to weigh mechanisms versus outcomes, how to evaluate diet sodas and non-nutritive sweeteners in context, and a range of listener questions covering health fads, emotional health, and sleep routines.
If you're not a subscriber and are listening on a podcast player, you'll only be able to hear a preview of the AMA. If you're a subscriber, you can now listen to this full episode on your private RSS feed or our website at the AMA #82 show notes page. If you are not a subscriber, you can learn more about the subscriber benefits here.
We discuss:
Overview of episode topics, emphasizing the goal of providing actionable, real-world health guidance  [1:30];
How health priorities and training strategies should evolve from early adulthood through older age [2:45];
Comparing the four major chronic diseases: which are most preventable, most uncertain, and most concerning [8:00];
Emerging strategies for dementia prevention: biomarkers, early detection, and new pharmacologic approaches [15:00];
How to use wearable data effectively: when it's helpful, when it's not, and how to avoid over-reliance [19:00];
DEXA scans: timing, interpretation, and limitations in body composition and bone density tracking [23:00];
Best practices for building sustainable health habits [30:15];
How to train your balance and stability [33:30];
How to recover from injuries and use setbacks to build strength and resilience [36:15];
High protein intake and the impact on mTOR: evaluating mechanisms versus real-world evidence on longevity [38:30];
Diet soda and artificial sweeteners: evaluating risks, benefits, and the importance of context [47:00];
How to balance enjoying life today with making choices that support long-term health and longevity [51:45]; and
More.
Connect With Peter on Twitter, Instagram, Facebook and YouTube

View the Show Notes Page for This Episode
Become a Member to Receive Exclusive Content
Sign Up to Receive Peter's Weekly Newsletter
In this special episode, Peter takes a deep dive into obicetrapib, an investigational drug that has captured his attention and renewed interest in an entire class of therapies known as CETP inhibitors. He explains what obicetrapib is and how it works, revisits the history of CETP inhibitors and why earlier versions of these drugs failed—sometimes dramatically—and breaks down the key clinical trials designed to evaluate their impact on cardiovascular risk. Peter examines how obicetrapib influences major lipid biomarkers, including LDL cholesterol and lipoprotein(a) [Lp(a)], and discusses emerging evidence from a study that explored the drug's effects on Alzheimer's-related blood biomarkers. He also highlights intriguing findings in individuals carrying the APOE4 allele and reflects on what these early results may mean for both cardiovascular disease prevention and potential implications for Alzheimer's risk, as well as how he is thinking about this therapy in the context of caring for his own patients.
We discuss:
Introducing obicetrapib: CETP inhibitor history, lipid biology, and early Alzheimer's biomarker signals in APOE4 carriers [2:15];
CETP biology explained: lipoproteins, reverse cholesterol transport, and how CETP inhibition alters HDL and LDL particles [5:15];
The early CETP inhibitor story: why raising HDL cholesterol alone failed to deliver cardiovascular protection [13:45];
The rise and fall of early CETP inhibitors: torcetrapib, dalcetrapib, evacetrapib, and anacetrapib [18:30];
Why obicetrapib may succeed where earlier CETP inhibitors failed [23:30];
The BROADWAY trial: obicetrapib's effects on LDL, ApoB, Lp(a), and residual cardiovascular risk [26:00];
Brain lipid metabolism and APOE4: how CETP inhibition may influence cholesterol transport in Alzheimer's disease [30:45];
Findings from the substudy of the BROADWAY trial which looked at changes in biomarkers of Alzheimer's disease [40:00];
Interpreting the BROADWAY Alzheimer's biomarker results: limitations, cautious optimism, and the need for a dedicated prevention trial [46:45];
Why Peter is optimistic about obicetrapib: cardiovascular benefits, Lp(a) reduction, and the path toward approval [50:00]; and
More.
Connect With Peter on Twitter, Instagram, Facebook and YouTube